International Journal of Medical Imaging

| Peer-Reviewed |

PET/CT Versus CT In Post-Operative Follow Up Of Breast Cancer Patients

Received: 23 February 2015    Accepted: 09 March 2015    Published: 13 March 2015
Views:       Downloads:

Share This Article

Abstract

Objectives: The aim of this work is to compare the sensitivity and specificity of CT alone versus PET/CT in post-operative follow up of breast cancer patients. Background: Positron emission tomography (PET), using 18F-fluorodeoxyglucose (FDG) is based on the principle of increased glucose metabolism in malignant tumors and has been frequently investigated in breast cancer. Materials & Methods: Thirty female patients with breast cancer have been investigated. All patients had positive operative history. PET/CT studies were performed for post-operative follow up. The inclusion criteria in this study are histologically proved breast cancer, positive operative history and normal blood urea and creatinine levels. Exclusion criteria is pregnancy and renal impairment. Patients were divided into three groups, first group FDG PET/CT was requested for non-conclusive CT findings, second group patients referred for FDG PET/CT for elevated tumor markers, while in third group FDG PET/CT was requested for follow up after chemotherapy and/or radiotherapy. Results: A comparison of the sensitivity and specificity for CT alone versus PET/CT in each group, in the first group CT alone had sensitivity and specificity of 90% and 12.5% respectively, while PET/CT had sensitivity and specificity 100%. In the second group CT alone had sensitivity and specificity of 57% and 100% respectively, while PET/CT had sensitivity and specificity of 100%. In group three, CT alone had sensitivity and specificity of 83.3% and 84.25%, respectively and PET/CT had sensitivity of 83.3% and specificity of 100%.Conclusions: PET/CT is more sensitive and specific than CT alone for post-operative follow up of breast cancer patients.

DOI 10.11648/j.ijmi.20150302.14
Published in International Journal of Medical Imaging (Volume 3, Issue 2, March 2015)
Page(s) 28-33
Creative Commons

This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.

Copyright

Copyright © The Author(s), 2024. Published by Science Publishing Group

Keywords

Positron Emission Tomography, Computed Tomography, Breast

References
[1] Hala S El Rebey, Hayam A Aiad, Nancy Y Asaad, Moshira M Abd El-Wahed, Iman L Abulkheir, Fatma M Abulkasem, et al. Immunohistochemical expression of topoisomerase II a and tissue inhibitor of metalloproteinases 1 in locally advanced breast carcinoma, Menoufia Medical Journal 2014; 27: 1.
[2] Gallowitsch HJ, Kresnik E, Gasser J, Kumnnig G, Igerc I, Mikosch P, et al. F-18 fluorodeoxyglucose positron-emission tomography in the diagnosis of tumor recurrence and metastases in the follow-up of patients with breast carcinoma: a comparison to conventional imaging. Acta Radiol 2003; 38(5):250.
[3] Murakami R, Kumita S, Yoshida T, Ishihara K, Kiriyama T, Hakozaki K et al. FDG-PET/CT in the diagnosis of recurrent breast cancer. Acta Radiol 2011; 53(1):12.
[4] Segaert I, Mottaghy F, Ceyssens S, De Wever W, Stroobants S, Van Ongeval C et al. Additional value of PET-CT in staging breast cancer. Experimental and therapeutic medicine 2010;16:617.
[5] Hodgson NC, GulenchynKY. Is there a role for positron emission tomography in breast cancer staging? Clinical oncology 2008; 26:721.
[6] Isasi CR, Moadel R, Blaufox M: A meta-analysis of FDG-PET for the evaluation of breast cancer recurrence and metastases. Breast Cancer Res Treat 2005; 90:105.
[7] Buck AK, Herrmann K, Stargardt T, Dechow T, Krause BJ, Schreyögg J. Economic evaluation of PET and PET/CT in oncology. J Nucl Med 2010; 51:401.
[8] Radan L, Ben-Haim S, Bar-Shalom R, Guralnik L, Israel O. The role of FDG-PET/CT in suspected recurrence of breast cancer. Cancer 2006; 107(11):2545.
[9] Na Young Jung,Ie Ryung Yoo,Bong Joo Kang,Sung Hun Kim,Byung Joo Chae,Ye Young Seo. Clinical significance of FDG-PET/CT at the postoperative surveillance in the breast cancer patients, Radiographics. 2014; 24:1411.
[10] Pennant M, Takwoingi Y, Pennant L, Davenport C, Fry-Smith A, Eisinga A, et al. A systematic review of positron emission tomography (PET) and positron emission tomography/computed tomography (PET/CT) for the diagnosis of breast cancer recurrence. Health Technol Assess 2010; 14:1.
[11] Veit-Haibach P, Antoch G, Beyer T, Stergar H, Schleucher R, Hauth EA. FDG-PET/CT in restaging of patients with recurrent breast cancer: possible impact on staging and therapy. Br J Radiol 2007; 80(955):508.
[12] Cheung K, Graves CRL, Robertson JFR. Tumor marker measurements in the diagnosis and monitoring of breast cancer. Cancer Treat Rev 2000; 26:91.
[13] Kurata A, Murata Y, Kubota K, Osanai T, Shibuya H. Multiple 18F-FDG PET-CT for postoperative monitoring of breast cancer patients, Acta Radiol 2009; 50: 979, DOI: 10.3109/02841850903147046
[14] Champion L, Brain E, Giraudet AL, Le Stanc E, Wartski M, Edeline V, et al. Breast cancer recurrence diagnosis suspected on tumor marker rising: value of whole-body 18FDG-PET/CT imaging and impact on patient management. Cancer 2011; 117:1621.
[15] Filippi V, Malamitsi J, Vlachou F, Laspas F, Georgiou E, Prassopoulos V et al. The impact of FDG-PET/CT on the management of breast cancer patients with elevated tumor markers and negative or equivocal conventional imaging modalities. Nucl Med Commun, 2011; 32(2):85.
[16] Gallowitsch HJ, Kresnik E, Gasser J, Kumnig G, Igerc I, Mikosch P et al. [F-18]-fluorodeoxyglucose positron-emission tomography in the diagnosis of tumor recurrence and metastases in the follow-up of patients with breast carcinoma: a comparison to conventional imaging. Invest Radiol; 2003; 38(5):250.
[17] Cook G, Houston S, Rubens R, M N Maisey, I Fogelman. Detection of bone metastases in breast cancer by 18FDG PET: differing metabolic activity in osteoblastic and osteolytic lesions, Journal of Clinical Oncology. 1998; 16, (10):3375.
[18] Nakai T, Okuyama C, Kubota T, Yamada K, Ushijima Y, Taniike K et al. Pitfalls of FDG-PET for the diagnosis of osteoblastic bone metastases in patients with breast cancer. Eur.J.Nuc.Med.Mol.Imaging 2005; 32:1253.
[19] Yang SN, Liang JA, Lin FJ, Kao CH, Lin CC, Lee CC. comparing whole body [F-18]-2-deoxyglucose positron emission tomography and [technetium-99m]-methylene diphosphonate bone scan to detect bone metastases in patients with breast cancer. J Cancer Res Clin Oncol; 2002; 128(6):325.
[20] Port ER, Yeung H, Gonen M, Liberman L, Caravelli J, Borgen P, et al. 18F-2-fluoro-2-deoxy-D-glucose positron emission tomography scanning affects surgical management in selected patients with high-risk, operable breast carcinoma. Ann Surg Oncol. 2006; (5):677.
[21] Greco M, Crippa F, Agresti R. Axillary lymph node staging in breast cancer by 2-Fluoro-2- deoxy-D-glucose-positron emission tomography: Clinical evaluation and alternative management. J Natl Cancer Inst. 2001; 93(8):630.
[22] Andrei I, Rinat M, Sravanthi K, Peter S. Breast MRI and 18F FDG PET/CT in the management of breast cancer. Annals of Nuclear Medicine. 2007;21;(1):33.
[23] Constantinidou A, Martin A, Sharma B, Johnston SR. Positron emission tomography/computed tomography in the management of recurrent/metastatic breast cancer: a large retrospective study from the Royal Marsden Hospital. Ann.Oncol.2011; 22:307.
Author Information
  • Department of Radiodiagnosis, Faculty of Medicine, Menoufia University, Menoufia, Egypt

  • Department of Radiodiagnosis, Faculty of Medicine, Menoufia University, Menoufia, Egypt

  • Department of Radiodiagnosis, Shareq El-Madina Hospital, Alexandria, Egypt

Cite This Article
  • APA Style

    Hala H. Mohamed, Osama M. Ebied, Mohamed A. Hussein. (2015). PET/CT Versus CT In Post-Operative Follow Up Of Breast Cancer Patients. International Journal of Medical Imaging, 3(2), 28-33. https://doi.org/10.11648/j.ijmi.20150302.14

    Copy | Download

    ACS Style

    Hala H. Mohamed; Osama M. Ebied; Mohamed A. Hussein. PET/CT Versus CT In Post-Operative Follow Up Of Breast Cancer Patients. Int. J. Med. Imaging 2015, 3(2), 28-33. doi: 10.11648/j.ijmi.20150302.14

    Copy | Download

    AMA Style

    Hala H. Mohamed, Osama M. Ebied, Mohamed A. Hussein. PET/CT Versus CT In Post-Operative Follow Up Of Breast Cancer Patients. Int J Med Imaging. 2015;3(2):28-33. doi: 10.11648/j.ijmi.20150302.14

    Copy | Download

  • @article{10.11648/j.ijmi.20150302.14,
      author = {Hala H. Mohamed and Osama M. Ebied and Mohamed A. Hussein},
      title = {PET/CT Versus CT In Post-Operative Follow Up Of Breast Cancer Patients},
      journal = {International Journal of Medical Imaging},
      volume = {3},
      number = {2},
      pages = {28-33},
      doi = {10.11648/j.ijmi.20150302.14},
      url = {https://doi.org/10.11648/j.ijmi.20150302.14},
      eprint = {https://download.sciencepg.com/pdf/10.11648.j.ijmi.20150302.14},
      abstract = {Objectives: The aim of this work is to compare the sensitivity and specificity of CT alone versus PET/CT in post-operative follow up of breast cancer patients. Background: Positron emission tomography (PET), using 18F-fluorodeoxyglucose (FDG) is based on the principle of increased glucose metabolism in malignant tumors and has been frequently investigated in breast cancer. Materials & Methods: Thirty female patients with breast cancer have been investigated. All patients had positive operative history. PET/CT studies were performed for post-operative follow up. The inclusion criteria in this study are histologically proved breast cancer, positive operative history and normal blood urea and creatinine levels. Exclusion criteria is pregnancy and renal impairment. Patients were divided into three groups, first group FDG PET/CT was requested for non-conclusive CT findings, second group patients referred for FDG PET/CT for elevated tumor markers, while in third group FDG PET/CT was requested for follow up after chemotherapy and/or radiotherapy. Results: A comparison of the sensitivity and specificity for CT alone versus PET/CT in each group, in the first group CT alone had sensitivity and specificity of 90% and 12.5% respectively, while PET/CT had sensitivity and specificity 100%. In the second group CT alone had sensitivity and specificity of 57% and 100% respectively, while PET/CT had sensitivity and specificity of 100%. In group three, CT alone had sensitivity and specificity of 83.3% and 84.25%, respectively and PET/CT had sensitivity of 83.3% and specificity of 100%.Conclusions: PET/CT is more sensitive and specific than CT alone for post-operative follow up of breast cancer patients.},
     year = {2015}
    }
    

    Copy | Download

  • TY  - JOUR
    T1  - PET/CT Versus CT In Post-Operative Follow Up Of Breast Cancer Patients
    AU  - Hala H. Mohamed
    AU  - Osama M. Ebied
    AU  - Mohamed A. Hussein
    Y1  - 2015/03/13
    PY  - 2015
    N1  - https://doi.org/10.11648/j.ijmi.20150302.14
    DO  - 10.11648/j.ijmi.20150302.14
    T2  - International Journal of Medical Imaging
    JF  - International Journal of Medical Imaging
    JO  - International Journal of Medical Imaging
    SP  - 28
    EP  - 33
    PB  - Science Publishing Group
    SN  - 2330-832X
    UR  - https://doi.org/10.11648/j.ijmi.20150302.14
    AB  - Objectives: The aim of this work is to compare the sensitivity and specificity of CT alone versus PET/CT in post-operative follow up of breast cancer patients. Background: Positron emission tomography (PET), using 18F-fluorodeoxyglucose (FDG) is based on the principle of increased glucose metabolism in malignant tumors and has been frequently investigated in breast cancer. Materials & Methods: Thirty female patients with breast cancer have been investigated. All patients had positive operative history. PET/CT studies were performed for post-operative follow up. The inclusion criteria in this study are histologically proved breast cancer, positive operative history and normal blood urea and creatinine levels. Exclusion criteria is pregnancy and renal impairment. Patients were divided into three groups, first group FDG PET/CT was requested for non-conclusive CT findings, second group patients referred for FDG PET/CT for elevated tumor markers, while in third group FDG PET/CT was requested for follow up after chemotherapy and/or radiotherapy. Results: A comparison of the sensitivity and specificity for CT alone versus PET/CT in each group, in the first group CT alone had sensitivity and specificity of 90% and 12.5% respectively, while PET/CT had sensitivity and specificity 100%. In the second group CT alone had sensitivity and specificity of 57% and 100% respectively, while PET/CT had sensitivity and specificity of 100%. In group three, CT alone had sensitivity and specificity of 83.3% and 84.25%, respectively and PET/CT had sensitivity of 83.3% and specificity of 100%.Conclusions: PET/CT is more sensitive and specific than CT alone for post-operative follow up of breast cancer patients.
    VL  - 3
    IS  - 2
    ER  - 

    Copy | Download

  • Sections